Cardiovascular outcomes in 4 major trials of SGLT-2 inhibitors
| EMPA-REG OUTCOME21 | CANVAS22 | DECLARE-TIMI 5823 | VERTIS-CV24 | |
|---|---|---|---|---|
| Population | Type 2 diabetes + cardiovascular disease | Type 2 diabetes + cardiovascular disease or multiple risk factors for it | Type 2 diabetes + cardiovascular disease or multiple risk factors for it | Type 2 diabetes + cardiovascular disease |
| Number of patients | 7,020 | 10,142 | 17,160 | 8,246 |
| History of cardiovascular disease | 99% | 65.6% | 40.6% | 100% |
| History of heart failure | 10.1% | 14.4% | 10.2% | 23.7% |
| Outcomes with SGLT-2 inhibitor | ||||
| MACE (relative risk reduction) | 14% | 14% | Not significant | Not significant |
| MACE (number needed to treat) | 63 | 217 | Not available | Not available |
| Cardiovascular death (relative risk reduction) | 38% Not | significant | Not significant | Not significant |
| Hospitalization for heart failure (relative risk reduction) | 35% | 35% | 27% | 30% |
| Hospitalization for heart failure (number needed to treat) | 71 | 312 | 125 | 91 |
CANVAS = Canagliflozin Cardiovascular Assessment Study; DECLARE-TIMI 58 = Dapagliflozin Effect on Cardiovascular Events; EMPA-REG OUTCOME = Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients; MACE = major atherosclerotic cardiovascular events; VERTIS CV = Evaluation of Ertugliflozin Efficacy and Safety Cardiovascular Outcomes